CL2A-SN38 CAS:1279680-68-0 is a novel SN38 derivative featuring a maleimide-polyethylene glycol (Mal-PEG) attached peptide linker, designed for facile conjugation with antibodies to form antibody-drug conjugates (ADCs). SN38, a highly potent DNA topoisomerase I inhibitor, confers substantial antitumor capabilities. The CL2A linker’s unique pH-sensitive cleavability and disulfide bond formation with cysteine residues contribute to its enhanced performance.
Introduction to the application:
In pharmaceutical research and development, CL2A-SN38 has emerged as a promising ADC component for targeted cancer therapy. The innovative structure of the CL2A-SN38 complex enables accurate delivery of the potent SN38 cytotoxic agent to cancer cells, effectively combating a wide range of human solid tumors. The pH-sensitive cleavable CL2A linker ensures both stability in the bloodstream and selective release within the tumor microenvironment, promoting a bystander effect that enhances overall treatment efficacy. This breakthrough ADC platform is paving the way for safer and more effective cancer therapeutics.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
